News

GLP-1 receptor agonists may increase incidence of diabetic retinopathy while reducing its complications

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...
ScienceAlert on MSN19h

Scientists May Have Identified a Natural Alternative to Ozempic

Glucagon-like peptide-1 (GLP-1) is a hormone that is naturally produced by the body and which helps regulate blood sugar ...
News-Medical.Net on MSN3h

Study supports pre-surgery use of GLP-1 RAs for weight reduction

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...
HealthDay on MSN15h

GLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

Obese surgical patients can safely use GLP-1 therapy to reduce risk of complications, study concludes

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

GLP-1 microdosing for weight loss: Experts weigh the pros and cons

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?
EurekAlert!1d

Obese surgical patients’ medication lifeline can reduce risk - study

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of surgical complications linked to their obesity.
TCTMD5d

Oral GLP-1 Drug Yields 12% Weight Loss in Nondiabetic Patients With Obesity

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...
Science Daily4d

What really happens to your body when you stop weight loss drugs like Ozempic

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...
News-Medical.Net on MSN1d

Brain’s energy control map offers blueprint for next-gen weight loss therapies

Scientists map how the brain integrates hormonal and neural signals from the body to control appetite, energy use, and reward ...

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / ...
Pharmabiz5d

Eli Lilly announces positive results from phase 3 ATTAIN-1 trial of orforglipron, an oral GLP-1 receptor agonist to treat obesity

Eli Lilly announces positive results from phase 3 ATTAIN-1 trial of orforglipron, an oral GLP-1 receptor agonist to treat obesity: Indianapolis Friday, August 8, 2025, 09:00 Hrs [ ...